Relationship between Patients’ Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Table 3

Differences in overall survival associated with immunotherapy in age by subgroups.

		Participants, no.		Pooled HR (95% CI) for ICI vs. controlled therapies		Test for difference
Variable	Studies, no.	<65	≥65	<65	≥65	value
Overall	18	7092	5715	0.74 (0.68, 0.81)	0.80 (0.75, 0.86)	0.17
Line of therapy
First	11	4286	3561	0.74 (0.65, 0.85)	0.80 (0.73, 0.87)	0.351
Subsequent	7	2806	2154	0.73 (0.64, 0.83)	0.80 (0.69, 0.92)	0.367
Intervention therapy
ICI alone	11	4268	3369	0.74 (0.66, 0.83)	0.78 (0.72, 0.85)	0.468
ICI combined with non-ICI	7	2824	2346	0.73 (0.63, 0.86)	0.83 (0.74, 0.94)	0.203
Pathologic types
Squamous	4	1112	973	0.69 (0.53, 0.91)	0.82 (0.65, 1.05)	0.358
Nonsquamous	5	2203	1664	0.74 (0.62, 0.88)	0.77 (0.67, 0.87)	0.72

Abbreviations: HR = hazard ratio; ICI = immune checkpoint inhibitor.